A Novel Workflow to Assess Serum Stability of Antibody–siRNA Conjugates
Journal of the American Society for Mass Spectrometry · 04.11.2026 · 37 (11) · 2840-2850
DOI: 10.1021/jasms.6c00288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society for Mass Spectrometry, online erschienen am 18.10.2026. Verfasst von Yihan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative, Translational & ADME Sciences, AbbVie, South San Francisco, California94080, United States. Hauptthemen laut MEDLINE: RNA, Small Interfering, Immunoconjugates, Antibodies. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Antibody–siRNA conjugates (ARCs) are emerging as a promising approach for targeted delivery of small interfering RNA (siRNA) to specific cells outside the liver, harnessing the advantages of antibody-based delivery to overcome limitations inherent to siRNA molecules, including rapid degradation, limited tissue penetration, and poor specificity. To address the critical need for robust stability assessment of ARCs in biological matrices, we developed a novel in vitro serum stability assay featuring immunoaffinity purification that purified a tool molecule, ARC1, under neutral conditions from biological matrices to preserve the molecular integrity and prevent artificial degradation. The purified ARC1 was analyzed in three complementary liquid chromatography–high-resolution mass spectrometry (LC-HRMS) methods: native mass spectrometry, protein mass spectrometry, and oligonucleotide mass spectrometry. This assay enabled assessment of each individual ARC component, including the parental antibody, linker, sense strand, and antisense strand. The results demonstrated that the linker remained stable in serum for 4 days, while hydrolysis of the conjugated siRNA occurred in both sense and antisense strands. Various biotransformation products were identified by mapping the results from three LC-HRMS methods to visualize the degradation pathway of ARC1. This work represents the first in vitro serum stability analysis workflow of ARCs that can capture biotransformation of each ARC component using immunoaffinity purification. This method offers a valuable tool to proactively identify potential liabilities in ARC designs and inform ARC candidate selection, siRNA engineering, and strategic planning for bioanalytical, toxicity, and immunogenicity assessment during drug discovery and early development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Quantitative, Translational & ADME Sciences, AbbVie, South San Francisco, California94080, United States.
- Department of Small Molecule Therapeutics and Platform Technologies, AbbVie, Worcester, Massachusetts01605, United States.
- Department of Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, Illinois60064, United States.
ORCID-Profile: Yihan Li, Lu Wang, Hetal Sarvaiya
Zitieren
APA
Li, Y., Wang, L., Phipps, C. J., & Sarvaiya, H. (2026). A Novel Workflow to Assess Serum Stability of Antibody–siRNA Conjugates. Journal of the American Society for Mass Spectrometry, 37(11), 2840-2850. https://doi.org/10.1021/jasms.6c00288
Vancouver
Li Y, Wang L, Phipps CJ, Sarvaiya H. A Novel Workflow to Assess Serum Stability of Antibody–siRNA Conjugates. Journal of the American Society for Mass Spectrometry. 2026;37(11):2840-2850. doi:10.1021/jasms.6c00288
BibTeX
@article{Li2026,
author = {Li, Yihan and Wang, Lu and Phipps, Colin J and Sarvaiya, Hetal},
title = {A Novel Workflow to Assess Serum Stability of Antibody–siRNA Conjugates},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2026},
volume = {37},
number = {11},
pages = {2840--2850},
doi = {10.1021/jasms.6c00288}
}
EUVIMED